FierceBiotech9h
Insilico's AI-designed med tied to respiratory health improvements in midstage lung disease trial
Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...
FierceBiotech16h
GSK inks Parkinson's pact with Flagship's Vesalius for $570M-plus biobucks
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
FierceBiotech13h
Centessa drops phase 2 hemophilia B drug in wake of Pfizer’s Hympavzi approval
Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...
FierceBiotech15h
Roche teams up with transcription factor trailblazer Flare in new $1.8B-plus cancer pact
Since the 2023 financing round, Flare’s lead program FX-909 has moved into a phase 1 clinical trial for patients with ...
FierceBiotech15h
Third Rock-backed Trace uses $101M series A to go after same ALS target as Lilly
Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.
FierceBiotech22h
Merck KGaA's phase 3 rare tumor trial hits goal, teeing up rivalry with Daiichi and Ono
Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...
FierceBiotech15h
Novo Holdings, OrbiMed, Jeito lead $181M fundraise for ADC biotech
Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two ...
FierceBiotech14h
Novartis pays Schrödinger $150M, bets billions on the back end to form drug discovery pact
Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...